The neurobiology of schizophrenia: new leads and avenues for treatment

Bray, Nicholas John ORCID: https://orcid.org/0000-0002-4357-574X, Leweke, F. Markus, Kapur, Shitij and Meyer-Lindenberg, Andreas 2010. The neurobiology of schizophrenia: new leads and avenues for treatment. Current Opinion in Neurobiology 20 (6) , pp. 810-815. 10.1016/j.conb.2010.09.008

Full text not available from this repository.

Abstract

Recent large-scale genetic studies have provided robust evidence implicating several novel susceptibility genes for schizophrenia. These include ZNF804A, TCF4 and NRGN, which contain common variants that weakly increase schizophrenia susceptibility, and NRXN1, in which rare copy number variants have a greater impact on schizophrenia risk. Investigation of these and other substantiated susceptibility genes are providing valuable insight into the primary neurobiological mechanisms underlying schizophrenia, which may lead to novel therapeutic interventions for the disorder. In the meantime, several novel pharmacological strategies, including activation of mGluRs, elevation of synaptic glycine and inhibition of phosphodiesterase 10A, have recently shown promise for the treatment of schizophrenia in clinical trials.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) Neuroscience and Mental Health Research Institute (NMHRI) Medicine
Subjects:	Q Science > QH Natural history > QH426 Genetics R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Publisher:	Elsevier
Last Modified:	31 Oct 2022 09:44
URI:	https://orca.cardiff.ac.uk/id/eprint/82238

Citation Data

Cited 18 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item